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and intensifies cardiac remodeling and oxidative
stress in aged spontaneously hypertensive rats
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Background: The combination of systemic arterial hypertension and diabetes mellitus (DM) induces greater cardiac
remodeling than either condition alone. However, this association has been poorly addressed in senescent rats.
Therefore, this study aimed to analyze the influence of streptozotocin-induced DM on ventricular remodeling and
oxidative stress in aged spontaneously hypertensive rats (SHR).
Methods: Fifty 18 month old male SHR were divided into two groups: control (SHR, n = 25) and diabetic (SHR-DM,
n = 25). DM was induced by streptozotocin (40 mg/kg, i.p.). After nine weeks, the rats underwent echocardiography
and myocardial functional study in left ventricular (LV) isolated papillary muscle preparations. LV samples were
obtained to measure myocyte diameters, interstitial collagen fraction, and hydroxyproline concentration. Gene
expression of atrial natriuretic peptide (ANP) and α- and β-myosin heavy chain (MyHC) isoforms was evaluated by
RT-PCR. Serum oxidative stress was assessed by measuring lipid hydroperoxide concentration and superoxide
dismutase and glutathione peroxidase activities. Statistics: Student’s t test or Mann-Whitney test, p < 0.05.
Results: SHR-DM presented higher blood glucose (487 ± 29 vs. 89.1 ± 21.1 mg/dL) and lower body weight (277 ± 26
vs. 339 ± 38 g). Systolic blood pressure did not differ between groups. Echocardiography showed LV and left atrial
dilation, LV diastolic and relative wall thickness decrease, and LV systolic and diastolic function impairment in
SHR-DM. Papillary muscle study showed decreased myocardial contractility and contractile reserve in SHR-DM.
Myocyte diameters and myocardial interstitial collagen fraction and hydroxyproline concentration did not differ
between groups. Increased serum pro-oxidant activity and gene expression of ANP and β/α-MyHC ratio were
observed in DM.
Conclusion: Diabetes mellitus induces cardiac dilation and functional impairment, increases oxidative stress and
activates fetal gene program in aged spontaneously hypertensive rats.
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Heart failure represents a major public health issue
reaching epidemic proportions especially in elderly popu-
lations [1]. The prevalence of risk factors for cardiac fail-
ure is increasing at an alarming rate. Diabetes mellitus
(DM) and systemic arterial hypertension, important pre-
disposing factors, are associated with increased morbidity
and mortality [1].
Diabetes mellitus is a major risk factor for the develop-
ment of coronary atherosclerosis and diabetic cardiomy-
opathy, a non-atherogenic myocardial disease. Diabetic
cardiomyopathy results from complex relationships be-
tween metabolic abnormalities that accompany diabetes
and their cellular consequences leading to alterations in
myocardial structure and function [2-5]. Diabetes in-
duced cardiac remodeling is characterized by myocardial
interstitial and perivascular fibrosis, myocyte hyper-
trophy, calcium handling and contractile proteins abnor-
malities, and abnormal cardiomyocytes loss by apoptosis
[2,6,7]. Hyperglycemia induced oxidative stress is an im-
portant pathological mechanism involved in diabetic car-
diomyopathy [2,8].
Diabetes in humans is often associated with systemic
arterial hypertension. The combination of DM and
hypertension induces greater structural and functional
cardiac damage than either condition alone [9]. This
condition has been called diabetic hypertensive cardio-
myopathy [2]. However, the physiopathology of diabetes
and hypertension induced cardiac injury is not com-
pletely understood. In experimental studies, diabetes in
hypertensive rodents has very often resulted in impaired
cardiac remodeling by exacerbating fibrosis, changing
pro-hypertrophic factors expression, and inducing in-
flammation, microvascular changes, and higher mortality
rate than isolated DM or hypertension [10-16]. Although
the prevalence of risk factors for cardiovascular disease
increases with age, the combined effects of diabetes and
hypertension on cardiac remodeling during senescence
have been poorly addressed.
One widely used experimental model for studying
hypertension and heart failure is the spontaneously
hypertensive rat (SHR) [17-19]. It presents early arterial
hypertension and left ventricular hypertrophy [20] which
evolves to heart failure during maturity and senescence.
As cardiac failure development is slow, SHRs are consid-
ered a useful model for mimicking clinical heart failure.
The aim of this study was to analyze the influence of
streptozotocin-induced DM on cardiac remodeling and
oxidative stress in aged SHR.
Methods
Experimental groups
Male SHR were obtained from the Central Animal
House at Botucatu Medical School, UNESP. All animalswere housed in a room under temperature control at
23°C and kept on a 12-hour light/dark cycle. Food and
water were supplied ad libitum. All experiments and
procedures were approved by the Ethics Committee of
Botucatu Medical School, UNESP, Botucatu, SP, Brazil.
Eighteen-month-old SHR were assigned into two groups:
control (SHR, n = 25) and diabetic (SHR-DM, n = 25).
Diabetes was induced by intraperitoneal injection of
streptozotocin (Sigma, St. Louis, MO, USA) at 40 mg/kg
body weight diluted in 0.01 M citrate buffer pH 4.5 [21].
The control group received intraperitoneal injection of ve-
hicle only. Seven days after streptozotocin administration,
blood glucose was measured by glucometer (Advantage®).
Only streptozotocin rats with glycemia >220 mg/dL were
considered diabetic and included in the study [22]. Rats
were studied nine weeks after streptozotocin administra-
tion. Previous studies in normotensive rats by our labora-
tory [23] and other authors [4] have shown dilated left
ventricle and impaired systolic function 8-9 weeks after
streptozotocin injection.
Systolic arterial pressure was measured before
streptozotocin injection and at the end of experiment
by tail-cuff method using a model 709-0610 electro-
sphygmomanometer (Narco Bio-System®, International
Biomedical Inc., USA).
Echocardiographic study
Echocardiographic evaluation was performed in all rats
using a commercially available echocardiograph (General
Electric Medical Systems, Vivid S6, Tirat Carmel, Israel)
equipped with a 5-11.5 MHz multifrequency probe, as
previously described [19,24,25]. Rats were anesthetized
by intramuscular injection of a mixture of ketamine
(50 mg/kg) and xylazine (0.5 mg/kg). A two-dimensional
parasternal short-axis view of the LV was obtained at the
level of the papillary muscles. M-mode tracings were
obtained from short-axis views of the LV at or just below
the tip of the mitral-valve leaflets, and at the level of the
aortic valve and left atrium [26]. M-mode images of the
LV were printed on a black-and-white thermal printer
(Sony UP-890MD) at a sweep speed of 100 mm/s. All
LV structures were manually measured by the same ob-
server as previously described [26]. Values obtained were
the mean of at least five cardiac cycles on M-mode trac-
ings. The following structural variables were measured:
left atrium diameter (LA), LV diastolic and systolic di-
ameters (LVDD and LVSD, respectively), LV diastolic
posterior wall thickness (PWT), LV diastolic anterior
wall thickness (AWT), and aortic diameter (AO). Left
ventricular weight (LVW) was calculated using the for-
mula [(LVDD + PWT+AWT)3 – (LVDD)3] × 1.04 [27].
Left ventricular function was assessed by the following
parameters: endocardial fractional shortening (FS), ejec-
tion fraction (EF), posterior wall shortening velocity
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(E and A waves), E/A ratio, E-wave deceleration time
(EDT), and isovolumetric relaxation time (IVRT). As body
weight differed between groups, cardiac structures were
presented in both absolute and values normalized to body
weight and tibia length (measured during euthanasia).
Myocardial functional evaluation
At the end of the experimental period, myocardial con-
tractile performance was evaluated in all rats using iso-
lated LV papillary muscle preparation as previously
described [28,29]. Rats were anesthetized (pentobarbital
sodium, 50 mg/kg, intraperitoneally) and decapitated.
Hearts were quickly removed and placed in oxygenated
Krebs-Henseleit solution at 28°C. Left ventricular anter-
ior or posterior papillary muscle was dissected free,
mounted between two spring clips, and placed vertically
in a chamber containing Krebs-Henseleit solution at
28°C and oxygenated with a mixture of 95% O2 and 5%
CO2 (pH 7.38). The composition of the Krebs-Henseleit
solution in mM was as follows: 118.5 NaCl, 4.69 KCl,
1.25 CaCl2, 1.16 MgSO4, 1.18 KH2PO4, 5.50 glucose,
and 25.88 NaHCO3. The spring clips were attached to a
Kyowa model 120 T-20B force transducer and a lever
system, which allowed for muscle length adjustment.
Preparations were stimulated 12 times/min at a voltage
10% above threshold.
After a 60-min period, during which the preparations
were permitted to shorten while carrying light loads, mus-
cles were loaded to contract isometrically and stretched to
the apices of their length-tension curves. After a 5-min
period, during which preparations performed isotonic
contractions, muscles were again placed under isometric
conditions, and the apex of the length-tension curve
(Lmax) was determined. A 15 minute period of stable iso-
metric contraction was imposed prior to the experimental
period. One isometric contraction was then recorded for
later analysis.
The following parameters were measured from the iso-
metric contraction: peak developed tension (DT, g/mm2),
resting tension (RT, g/mm2), time to peak tension (TPT,
ms), maximum tension development rate (+dT/dt,
g/mm2/s), and maximum tension decline rate (-dT/dt,
g/mm2/s). To evaluate contractile reserve, the mechanical
performance of papillary muscles was evaluated at basal
condition and after the following inotropic stimulation:
post-rest contractions, extracellular Ca2+ concentration in-
crease, and beta-adrenergic agonist isoproterenol added to
the nutrient solution.
Papillary muscle cross-sectional area (CSA) was calcu-
lated from muscle weight and length by assuming cylin-
drical uniformity and a specific gravity of 1.0. All force
data were normalized for muscle CSA. Papillary muscles
with CSA >1.7 mm2 were excluded from analysis asmuscles with CSA >1.7 mm2 can present central core
hypoxia and impaired functional performance.
Histologic analysis
Transverse LV sections were fixed in 10% buffered for-
malin and embedded in paraffin. Sections (5 μm thick)
were stained with hematoxylin–eosin and collagen-
specific stain picrosirius red (Sirius red F3BA in aqueous
saturated picric acid) [30]. In at least 50 myocytes from
each LV, where the nucleus could clearly be identified,
the smallest transverse diameters were measured [31].
On average, 20 microscopic fields were used to quantify
interstitial collagen fraction. Perivascular collagen was
excluded from this analysis [30,32]. Measurements were
performed using a Leica microscope (magnification 40×)
attached to a video camera and connected to a computer
equipped with image analysis software (Image-Pro Plus
3.0, Media Cybernetics, Silver Spring, MD, USA).
Myocardial hydroxyproline concentration
Myocardial hydroxyproline concentration was measured
to estimate myocardial collagen content. Hydroxyproline
was measured in LV tissue [28,33]. Briefly, tissue was dried
using a Speedvac Concentrator (SC 100) attached to a re-
frigerated condensation trap (TRL 100) and vacuum pump
(VP 100, Savant Instruments, Inc., Farmingdale, NY,
USA). Tissue dry weight was measured and samples were
hydrolyzed overnight at 100°C with 6 N HCl (1 mL/10 mg
dry tissue). An 50 μL aliquot of the hydrolysate was trans-
ferred to an Eppendorf tube and dried in the Speedvac
Concentrator. One milliliter of deionized water was added
and the sample transferred to a tube with a Teflon screw
cap. One milliliter of potassium borate buffer (pH 8.7) was
added to maintain constant pH and the sample was oxi-
dized with 0.3 mL of chloramine T solution at room
temperature for 20 minutes. The addition of 1 mL of
3.6 M/L sodium thiosulfate with thorough mixing for 10 s
stopped the oxidative process. The solution was saturated
with 1.5 g KCl. The tubes were capped and heated in boil-
ing water for 20 min. After cooling to room temperature,
the aqueous layer was extracted with 2.5 mL of toluene.
One and a half milliliter of toluene extract was transferred
to a 12 × 75 mm test tube. Then 0.6 mL of Ehrlich's re-
agent was added and color allowed to develop for 30 mi-
nutes. Absorbance was read at 565 nm against a reagent
blank. Deionized water and 20 μg/mL hydroxyproline
were used as the blank and standard, respectively.
Serum oxidative stress evaluation
Eight rats from each group were randomly chosen for
serum oxidative stress evaluation. During euthanasia,
blood samples were collected and centrifuged at 1,400 g
for 10 min. Aliquots of 0.5 mL serum were used to
measure lipid hydroperoxide concentration, which was
Table 1 Glucose, body weight and systolic blood pressure
Parameters SHR (n = 21) SHR-DM (n = 16) P value
Initial glucose (mg/dL) 95.1 ± 18.5 101 ± 8.88 0.461
Final glucose (mg/dL) 89.1 ± 21.1 487 ± 29 0.001
Initial BW (g) 370 ± 31 359 ± 22 0.118
Final BW (g) 339 ± 38 277 ± 26 0.001
Initial BP (mmHg) 203 ± 23 223 ± 43 0.139
Final BP (mmHg) 193 ± 34 201 ± 36 0.524
Data are expressed as mean ± standard deviation. SHR: spontaneously
hypertensive rats without diabetes mellitus; SHR-DM: SHR with diabetes
mellitus; BW: body weight; BP: systolic blood pressure. P value: result of
statistical test comparing SHR-DM vs SHR (Student’s t test).
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250 μM ammonium ferrous sulfate, 100 μM xylenol or-
ange, 25 mM sulfuric acid, and 4 mM butylated hydro-
xytoluene. The solution was incubated for 30 minutes at
room temperature and measured at 560 nm [34].
Glutathione peroxidase was assayed in 15 μL of serum
using 0.15 M phosphate buffer, pH 7.0, containing 5 mM
EDTA, 0.1 mL of 0.0084 M NADPH, 4 μg of GSSG-
reductase, 1.125 M sodium azide, and 0.15 M glutathione
reduced form in a total volume of 0.3 mL [35].
Superoxide dismutase activity was determined In
serum aliquots of 50 μL using its ability to inhibit reduc-
tion of nitroblue tetrazolium, in medium containing
50 mM phosphate buffer pH 7.4, 0.1 mM EDTA, 50 μM
NBT, 78 μM NADH, and 3.3 μM phenazine metho-
sulfate. One unit of superoxide dismutase was defined as
the amount of protein needed to decrease the reference
rate to 50% of maximum inhibition [36].
Enzyme activities were analyzed at 25°C using a
microplate reader system (μQuant-MQX 200 with KC
Junior software, Bio-TeK Instruments, Winooski, VT,
USA). All reagents were purchased from Sigma (St. Louis,
MO, USA).
Real time RT-PCR (transcription polymerase chain reaction
after reverse transcription) analysis
Ten rats from each group were randomly chosen for
gene expression analysis. Total RNA was extracted from
LV free wall with TRIzol Reagent (Invitrogen Life Tech-
nologies, Carlsbad, CA, USA) according to a previously
described method [37,38]. Frozen muscles were mechan-
ically homogenized on ice in 1 mL of ice-cold TRIzol re-
agent. Total RNA was solubilized in RNase-free H2O,
incubated in DNase I (Invitrogen Life Technologies) to
remove any DNA in the sample, and quantified by meas-
uring optical density at 260 nm. RNA purity was ensured
by obtaining a 260 ⁄ 280 nm optical density ratio of ap-
proximately 2.0. One microgram of RNA was reverse
transcribed using High Capacity cDNA Reverse Tran-
scription Kit in a total volume of 20 μL, according to
standard methods (Applied Biosystems, Foster City, CA,
USA). Aliquots of 2.5 μL (10–100 ng) of cDNA were
then submitted to real-time PCR reaction using 10 μL
2× TaqMan® Universal PCR Master Mix (Applied
Biosystems) and 1 μL of customized assay (20×)
containing sense and antisense primers and TaqMan
(Applied Biosystems) probe specific to each gene, sarco-
plasmic reticulum calcium ATPase (SERCA) [TaqMan
assay Rn00568762; Ref. seq. Genbank NM_017290], α-
myosin heavy chain isoform (α-MyHC) [TaqMan assay
Rn00568304_m1; Ref. seq. Genbank NM_017239.2], β-
myosin heavy chain isoform (β-MyHC) [TaqMan assay
Rn00568328_m1; Ref. seq. Genbank NM_017240.1],
and atrial natriuretic peptide (ANP) [TaqMan assayRn00561661_m1; Ref. seq. Genbank NM_012612.2].
Amplification and analysis were performed using Step
One PlusTM Real Time PCR System (Applied Biosystems)
according to manufacturer’s recommendation. As diabetes
can modulate heart GAPDH content [39], expression data
were normalized to cyclophilin expression [reference gene;
TaqMan assay Rn00690933_m1; Ref. seq. Genbank
NM_017101]. Reactions were performed in triplicate and
expression levels calculated using the CT comparative
method (2-ΔΔCT).
Statistical analysis
Comparisons between groups were performed by the
unpaired Student’s t test (expressed as mean ± standard
deviation) when data showed normal distribution. When
data showed non-normal distribution, comparisons be-
tween groups were made with the Mann-Whitney test
(expressed as median and 25th and 75th percentiles).
Results
During experiment, four SHR and six SHR-DM rats died.
Three SHR-DM rats presented glycemia <220 mg/dL and
were excluded from the study. At the end of the experi-
ment, the diabetic group presented higher blood glucose
and lower body weight than the control group. Systolic
blood pressure was not significantly different between
groups (Table 1).
Table 2 shows cardiac structure data obtained at the
end of the experiment. Heart rate was lower in the dia-
betic group. LV diastolic diameter normalized to body
weight, LV systolic diameter, and left atrial diameter-to-
body weight ratio were higher in the diabetic group. LV
posterior wall, septal diastolic, and relative wall thickness
were lower in SHR-DM. Tibia length, LV diastolic diam-
eter/tibia length ratio and left atrial diameter/tibia length
ratio did not differ between groups. LV functional data
are shown in Table 3. The parameters of systolic func-
tion endocardial fractional shortening, ejection fraction,
and posterior wall shortening velocity were lower in the
diabetic group. Diastolic function evaluation showed de-
creased mitral A-wave and increased E/A ratio and
Table 2 Echocardiographic structural data
Parameters SHR (n = 21) SHR-DM (n = 16) P value
HR (bpm) 322 ± 40 287 ± 40 0.010
LVDD (mm) 8.56 ± 1.03 8.73 ± 0.77 0.572
LVDD/BW (mm/kg) 24.2 (22.1 – 26.0) 31.2 (25.3 – 34.0) 0.001
LVDD/T (mm/cm) 2.02 ± 0.24 2.09 ± 0.19 0.445
LVSD (mm) 4.71 ± 1.27 5.54 ± 1.19 0.043
PWT (mm) 1.83 (1.75 – 1.90) 1.72 (1.66 – 1.79) 0.031
SWT (mm) 1.86 (1.77 – 1.91) 1.74 (1.66 – 1.83) 0.023
AO (mm) 4.50 (4.45 – 4.85) 4.45 (4.30 – 4.90) 0.701
LA (mm) 7.46 ± 1.12 7.51 ± 1.27 0.900
LA/BW (mm/kg) 21.5 ± 3.72 26.3 ± 5.82 0.003
LA/T (mm/cm) 1.75 ± 0.22 1.82 ± 0.33 0.513
LV mass (g) 1.24 (1.05 – 1.39) 1.18 (1.05 – 1.41) 0.673
LV mass/BW (g/Kg) 3.35 (3.12 – 4.04) 4.16 (3.27 – 5.05) 0.088
RWT 0.44 ± 0.07 0.40 ± 0.05 0.046
Tibia length (cm) 4.15 (4.10-4.19) 4.20 (4.10-4.20) 0.213
Data are expressed as mean ± standard deviation or median and 25th and 75th
percentile. SHR: spontaneously hypertensive rats without diabetes mellitus;
SHR-DM: SHR with diabetes mellitus; BW: body weight; HR: heart rate; LVDD
and LVSD: left ventricular (LV) diastolic and systolic diameter, respectively;
PWT: LV posterior wall thickness; SWT: LV septal wall thickness; AO: aortic
diameter; LA: left atrial diameter; LV mass: LV mass; RWT: relative wall
thickness; T: tibia length. P value: result of statistical test (Student’s t or
Mann-Whitney tests).
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tral E-wave and E-wave deceleration time (EDT) did not
differ between groups.
Papillary muscle functional data at basal condition with
extracellular calcium concentration of 1.25 mM showed
contractile impairment in SHR-DM characterized by
prolonged time to peak tension and decreased maximum
tension development rate. Peak developed tension, resting
tension, and maximum tension decline rate did not differTable 3 Echocardiographic left ventricular functional data
Parameters SHR (n = 21) SHR-DM (n = 16) P value
FS (%) 45.8 ± 9.35 37.1 ± 8.94 0.005
Ejection fraction 0.83 ± 0.08 0.74 ± 0.11 0.005
PWSV (mm/s) 30.9 ± 7.10 26.4 ± 5.94 0.039
E-wave (cm/s) 77.1 ± 25.2 92.9 ± 30.4 0.090
A-wave (cm/s) 72.2 ± 37.1 34.4 ± 20.5 0.001
E/A 0.75 (0.62 – 4.37) 1.41 (1.19 – 6.43) 0.014
EDT (ms) 38.1 ± 5.67 33.2 ± 7.09 0.132
IVRT (ms) 36.9 ± 7.60 43.4 ± 6.44 0.008
Data are expressed as mean ± standard deviation or median and 25th and 75th
percentile. SHR: spontaneously hypertensive rats without diabetes mellitus;
SHR-DM: SHR with diabetes mellitus; FS: endocardial fractional shortening;
PWSV: posterior wall shortening velocity; E: early diastolic mitral inflow
velocity; A: late diastolic mitral inflow velocity; EDT: E-wave deceleration time;
IVRT: isovolumetric relaxation time. P value: result of statistical test (Student’s t
or Mann-Whitney tests).between groups (Table 4). After positive inotropic stimula-
tion with 30 s post-rest contraction, increased extracellular
Ca2+ concentration (2.5 mM), and addition of 10-7 M iso-
proterenol to the nutrient solution, peak developed ten-
sion was lower in SHR-DM (Figure 1). After the three
inotropic interventions, maximum tension development
rate was smaller in SHR-DM, and maximum tension
decline rate and resting tension did not differ between
groups.
There was no significant difference between groups for
LV hydroxyproline concentration (SHR 6.68 ± 1:52; SHR-
DM 7.27 ± 2.28 mg/g; p = 0.50), interstitial collagen frac-
tion (SHR 9.00 ± 2.90; SHR-DM 13.3 ± 7.60%; p = 0.11),
and myocyte diameter [SHR 19.1 (17.0-22.4); SHR-DM
20.6 (19.6-21.0) μm; p = 0.62].
Serum oxidative stress parameters are presented in
Table 5. Lipid hydroperoxide concentration was higher
and superoxide dismutase and glutathione peroxidase
were lower in SHR-DM.
Gene expression of SERCA, α-MyHC, and β-MyHC
was not different between groups. The β-MyHC/α-
MyHC ratio and ANP gene expression were higher in
SHR-DM (Table 6).
Discussion
In this study we showed that streptozotocin-induced dia-
betes mellitus activates fetal gene program, increases
serum oxidative stress, and impairs left ventricular and
myocardial function in senescent spontaneously hyper-
tensive rats.
To the best of our knowledge, this is the first study to
evaluate the effects of streptozotocin-induced diabetes
mellitus on the aged SHR heart. The spontaneously
hypertensive rat is a well-established model of genetic
hypertension [17-19]. SHR develops early arterial hyper-
tension and left ventricular hypertrophy which evolve to
cardiac failure usually between 18-22 months of age
[18,40]. Taking into account the high prevalence of ar-
terial hypertension and diabetes mellitus co-existing inTable 4 Basal isolated papillary muscle data
Parameters SHR (n = 13) SHR-DM (n = 12) P value
DT (g/mm2) 5.60 (2.57 – 7.99) 3.05 (2.17 – 5.42) 0.121
RT (g/mm2) 0.92 ± 0.37 0.81 ± 0.27 0.383
TPT (ms) 236 ± 30 264 ± 24 0.024
+dT/dt (g/mm²/s) 43.2 ± 22.5 25.7 ± 15.4 0.033
-dT/dt (g/mm²/s) 19.5 ± 9.54 15.3 ± 6.96 0.229
CSA (mm2) 1.04 ± 0.38 1.13 ± 0.30 0.511
Data are expressed as mean ± standard deviation or median and 25th and 75th
percentile. SHR: spontaneously hypertensive rats without diabetes mellitus;
SHR-DM: SHR with diabetes mellitus; DT: peak developed tension; RT: resting
tension; TPT: time to peak tension; +dT/dt: maximum tension development
rate; -dT/dt: maximum tension decline rate; CSA: papillary muscle cross
sectional area. P value: result of statistical test (Student’s t or
Mann-Whitney tests).
Figure 1 Peak of developed tension (DT) during basal condition and after positive inotropic stimulation with 30 s post-rest
contraction, 2.5 mM extracellular Ca2+ concentration, and 10-7 M isoproterenol added to nutrient solution.
Table 6 Evaluation of mRNA by real time PCR
Variables SHR (n = 10) SHR-DM (n = 10) P value
SERCA 1.00 ± 0.71 1.79 ± 1.22 0.125
α-MyHC 1.00 ± 0.60 0.72 ± 0.45 0.294
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when rats are considered senescent [18].
Left ventricular and myocardial function
In vivo cardiac structures and systolic and diastolic func-
tion were analyzed by echocardiography. Diabetes melli-
tus increased LV systolic diameter without changing LV
diastolic diameter and left atrium diameter in both abso-
lute and values normalized to tibia length. When nor-
malized to body weight, LV diastolic diameter and left
atrium diameter were higher in SHR-DM than SHR.
Normalization of cardiac structural parameters to body
weight can lead to misinterpretation of results as cardiac
chambers diameters are not exactly proportional to body
weight [41]. Therefore, our data suggest that DM in-
creases LV systolic diameter without dilating LV or left
atrium in spontaneously hypertensive rats. LV posterior
wall and septal diastolic thickness and LV relative wall
thickness were lower in the diabetic group, while LV
mass did not differ between groups. These results dem-
onstrate that eccentric ventricular remodeling occurred
in diabetic rats. SHR-DM also presented LV systolic
function impairment, characterized by reduced endocar-
dial fractional shortening, ejection fraction and posterior
wall shortening velocity, and diastolic dysfunction char-
acterized by reduced mitral A wave and increased E/A
ratio and isovolumetric relaxation time. Eccentric ven-
tricular remodeling and impaired LV systolic andTable 5 Evaluation of oxidative stress
Variables SHR (n = 8) SHR-DM (n = 8) P value
Lipid hydroperoxide (nmol/ml) 8.80 ± 0.84 11.1 ± 1.04 0.001
Superoxide dismutase (U/mg) 687 ± 84 396 ± 50 0.001
Glutathione peroxidase (U/ml) 20.7 ± 1.98 17.6 ± 1.95 0.008
Data are expressed as mean ± standard deviation. SHR: spontaneously
hypertensive rats without diabetes mellitus; SHR-DM: SHR with diabetes
mellitus. P value: result of statistical test (Student’s t test).diastolic function are commonly observed in diabetic
cardiomyopathy in both clinical and experimental stud-
ies [2,4,42].
In this study, diabetes mellitus did not modulate blood
pressure, which in accordance with Wienen et al. [11] in
diabetic young SHR. Thus, we can discard blood pres-
sure changes participating in the cardiac alterations ob-
served in our SHR-DM.
Several pathophysiological mechanisms may be involved
in LV dilation and dysfunction during diabetes [43]. Im-
paired myocardial contractility is an important cause of
cardiac dilation and dysfunction [44]. In fact we found that
myocardial systolic function, evaluated in isolated papillary
muscle preparations, was depressed in diabetic rats, which
presented increased time to peak tension and decreased +
dT/dt. Contractile reserve was also impaired in SHR-DM
as developed tension, unchanged at basal condition, was
reduced after positive inotropic stimulation with post-rest
contraction, increased extracellular Ca2+ concentration,
and isoproterenol added to nutrient solution. Myocardial
diastolic function was unchanged. Isolated papillary muscle
preparations allow us to properly control preload and
afterload and thus analyze intrinsic myocardial function.β-MyHC 0.87 (0.70 – 1.17) 1.11 (0.78 – 1.28) 0.470
β-MyHC/α-MyHC 1.20 ± 0.60 2.26 ± 0.94 0.018
ANP 1.00 ± 0.38 1.88 ± 0.69 0.009
Data are expressed as mean ± standard deviation or median and 25th and 75th
percentile (arbitrary units). SHR: spontaneously hypertensive rats without
diabetes mellitus; SHR-DM: SHR with diabetes mellitus. SERCA: sarcoplasmic
reticulum calcium ATPase; MyHC: myosin heavy chain; ANP: atrial natriuretic
peptide; Cyclophilin: housekeeping gene used in standardizating target gene
transcript product quantity. P value: result of statistical test (Student’s t or
Mann-Whitney tests).
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tolic function in combination with ventricular eccentric re-
modeling is involved in diabetes-induced LV functional
impairment in aged SHR. Myocardial dysfunction has also
been reported in adult diabetic hypertensive and normo-
tensive rats [16,45].
In diabetes, several myocardial changes can be in-
volved in myocardial dysfunction such as oxidative
stress, myocardial fibrosis, fetal gene program activation,
myocyte hypertrophy, and extracellular matrix metallo-
proteinases changes [13,46].
Oxidative stress and fetal gene expression
Cardiac remodeling induced by diabetes and hypertension
has been associated with increased oxidative stress [45,47].
In this study, we found increased lipid hydroperoxide con-
centration, which indicates increased serum free radicals,
and a decrease in superoxide dismutase and glutathione
peroxidase activity in SHR-DM. Therefore, diabetes
mellitus increases myocardial oxidative stress in hyperten-
sive rats. Although a causative role could not be demon-
strated in this study, myocardial oxidative stress may have
been involved in impaired myocardial and ventricular
function in our SHR-DM. Studies have shown that in-
creased oxidative stress jeopardizes myocardial function
through mechanisms such as micro-vascular damage,
abnormalities in calcium homeostasis, and endothelial
dysfunction [8].
In this study, we observed a significant increase in
atrial natriuretic peptide (ANP) gene expression in SHR-
DM. Increased ANP gene expression has already been
reported in diabetic rats [48]. In our study, increased
ANP can be explained by the LV diastolic dysfunction
with consequent LV diastolic pressure increase and ANP
synthesis. There was no significant difference in SERCA,
and α- and β-myosin gene expression. However, β/α-
myosin gene expression ratio was higher in the diabetic
group. This is consistent with the notion that alterations
in glucose metabolism play a role in myosin heavy chain
isoform changes [49]. In fact, Connelly et al. [50] found
reduced α-myosin heavy chain and increased β-myosin
heavy chain and β/α-myosin heavy chain ratio in diabetic
rat hearts. Therefore, diabetes mellitus in SHR induces
gene expression changes toward fetal gene program. In
this study, the increased β/α-myosin ratio may have been
responsible for the increased time to peak tension ob-
served in SHR-DM papillary muscle.
In diabetes as well as in hypertension, the most prom-
inent myocardial histopathological feature is fibrosis,
which can be perivascular, interstitial, or both [8,51]. In
this study, myocardial collagen content evaluated by
myocardial hydroxyproline concentration and morfo-
metric analysis in picrosirius red stained slides showed
no significant difference between groups. These resultsare consistent with studies on the effects of combined
hypertension and DM in mice [10] and SHR [52]. It
should be pointed out that, although we found no sig-
nificant differences in collagen content between SHR
and SHR-DM, both groups presented increased myocar-
dial fibrosis against literature data from normotensive
rats [18,53,54]. Therefore, we can conclude that add-
itional fibrosis is not involved in diabetes-induced
impaired cardiac function in SHR.
Myocyte diameter was not different between groups.
Myocyte hypertrophy is a common finding in cardiomyop-
athy induced by type 2 diabetes. In streptozotocin-induced
diabetes, probably from hypoinsulinemia, myocardial hy-
pertrophy has not commonly been observed [55].
One limitation of this study is that streptozotocin-
induced type 1 DM is not the most common clinical situ-
ation in hypertensive aged patients. Type 1 and type 2 DM
can differentially affect the heart as decreased systolic per-
formance and delayed relaxation is more evident in type 1
DM and increased diastolic stiffness is remarkable in type
2 DM [56]. Therefore, additional studies are necessary to
confirm our results in hypertensive rats with type 2 DM.
Another limitation is the lack of LV end-diastolic pressure
measurement, which is considered the gold standard for
cardiac functional characterization [57]. Finally, the lower
heart rate in SHR-DM (11% lower than in SHR) could
have influenced left cardiac chamber sizes and LV func-
tion. However, isolated papillary muscle experiments,
which allow myocardial function evaluation independent
of cardiac load and heart rate, showed that systolic myo-
cardial function was impaired in SHR-DM, confirming
echocardiographic results.
Conclusion
In conclusion, this study shows the adverse effects of
type 1 diabetes when combined with genetic hyperten-
sion on cardiac remodeling in aged rats. Diabetes
mellitus induces left atrium and ventricle dilation, left
ventricular eccentric remodeling, and left ventricular
and myocardial functional impairment. Cardiac remodel-
ing is associated with increased oxidative stress and acti-
vated fetal gene program.
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